Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address: ul. Bonifraterska 17
00-203 Warszawa
Tel: 022 280 00 00
Sanofi-aventis is a global healthcare leader
Focused on patients’ needs, sanofi-aventis offers a range of essential healthcare assets, including a broad-based product portfolio and a presence worldwide.
At a glance
2010 sales: €30.384 billion
A broad portfolio of pharmaceutical products: prescription medicines, generics, consumer health care and animal health
World leader in human vaccines
A broad and balanced presence on both traditional and emerging markets
Around 102,000 employees in 100 countries
Group strategy
Our ambition is to become a diversified global healthcare leader. Our strategy is built around three priorities to reach its goals and ensure sustainable growth:
Innovation in Research and Development
Adaptation of Group structures
External growth opportunities
Prescription medicines
In 2010, pharmaceutical sales were of €26.676 million driven by the Group’s major prescription products in particular in the field of diabetes, oncology and thrombosis.
Among these, Lantus® confirms its position as the leading brand of insulin on the world market with sales of €3,510 million in 2010, boosted by the success of the SoloSTAR® pen injector. In the United-States, these figures include an accrual related to U.S. health care reform and were impacted by a reduction in inventory.
In January 2011, the FDA updated its ongoing safety review of Lantus®. In addition to the analysis of the four studies published in Diabetologia, the FDA also reviewed results from a five-year diabetic retinopathy clinical trial in patients with Type 2 Diabetes. At this time and based on these data, FDA has not concluded that Lantus increases the risk of cancer.
The range of products in the field of diabetes also includes Apidra® and Amaryl®.
The Group’s other major prescription drugs are Lovenox®, Taxotere®, Plavix®, Aprovel®, Eloxatin®, and Multaq®.
Jevtana®, a new anti-cancer agent, was approved on June 17, 2010 by the FDA following a priority review and launched in the U.S. on July 19, 2010 for patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-based therapy.
Human Vaccines
Sanofi Pasteur, the vaccines division of sanofi-aventis, is a global leader with the world’s broadest range of human vaccines.
Among the major vaccines there are the Polio/Pertussis/Hib vaccines such as Pentacel® and Pentaxim®, along with influenza vaccines (Vaxigrip® et Fluzone®) against seasonal flu, meningitis and pneumonia vaccines (incuding. Menactra®), adult booster vaccines (including Adacel ®) and travel and other endemics vaccines.
Year-to-date consolidated net sales for the Human Vaccines business were of €3,808 million.
Generics
In 2010, sales of the generics business grew to €1,534 million, due to acquisitions completed in 2009 and solid organic growth especially in Eastern Europe and Brazil as well as in the U.S where an authorized generic of Ambien®CR was launched during the period.
Consumer Healthcare
Sanofi-aventis is a mayor player in the global market of Consumer Healthcare. In 2010, the sales of this activity reached €2,217 million reflecting the contribution from the acquisitions of Chattem, Nepentes and Oenobiol.
The eight international brands² are: Doliprane®, Essentiale®, No-Spa®, Maalox®, Enterogermina®, Magne B6®, Dorflex®, and Lactacyd®.
Animal Health
Merial, a wholly-owned sanofi-aventis subsidiary is a leading producer of animal health products with Frontline® and Heartgard®. Merial posted net sales of 2,635 million US dollars in 2010.
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here